Skip to main content
. 2016 Sep 6;7(42):68597–68613. doi: 10.18632/oncotarget.11860

Figure 4. AZD9291 treatment is effective in erlotinib-resistant cells and induces EGFR degradation independent of kinase mutations.

Figure 4

A. NCI-H2347 (WT), SCCNC4 (S768-D770 dup), HCC827 (delE746-A750), and NCI-H1975 (L858R/T790M) cells harboring the above mentioned EGFR mutations were either treated with DMSO, erlotinib or AZD9291. Four days after treatment cellular viability was assessed using MTT assay and results were plotted relative to vehicle control. B. To assess the effect of AZD9291 on EGFR half-life, cell-lines described in Figure 4A were treated as described in Figure 3, and EGFR levels were measured. The mean half-life ± SEM from three independent experiments for each cell line is shown in the box.